| Recruiting | Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC) Soft Tissue Sarcoma | Phase 3 | 2023-11-29 |
| Recruiting | Study of ADI-PEG 20 Versus Placebo in Subjects With NASH Nonalcoholic Steatohepatitis (NASH) | Phase 2 | 2023-09-13 |
| Active Not Recruiting | Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia Acute Myeloid Leukemia, Adult | Phase 1 | 2022-04-05 |
| Recruiting | Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcin Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma | Phase 3 | 2022-03-14 |
| Active Not Recruiting | ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme Glioblastoma Multiforme (GBM) | Phase 2 | 2020-09-14 |
| Completed | Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin Mesothelioma | Phase 2 / Phase 3 | 2017-08-01 |
| Terminated | Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers Advanced Solid Cancers | Phase 1 | 2017-07-14 |
| Terminated | Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML Acute Myeloid Leukemia | Phase 1 | 2017-01-20 |
| Completed | PH 2 ADI-PEG 20 Acute Myeloid Leukemia Acute Myeloid Leukemia | Phase 2 | 2015-01-06 |
| Completed | Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer Advanced Pancreatic Cancer | Phase 1 | 2014-11-17 |
| Completed | Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer Hepatocellular Carcinoma | Phase 1 | 2014-11-01 |
| Terminated | Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carci Advanced Gastrointestinal (GI) Malignancies, Hepatocellular Carcinoma, Gastric Cancer | Phase 1 / Phase 2 | 2014-11-01 |
| Completed | Ph 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Vs TACE Alone in Patients With Unresectable Hepatocellular Carcinoma | Phase 2 | 2014-10-15 |
| Terminated | Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin Pleural Mesothelioma Malignant Advanced, Peritoneal Mesothelioma Malignant Advanced, Non-squamous Non-small Cell Lung Carcinoma | Phase 1 | 2014-04-23 |
| Completed | Ph 1 ADI-PEG 20 Plus Doxorubicin; Patients With HER2 Negative Metastatic Breast Cancer HER2 Negative Metastatic Breast Cancer | Phase 1 | 2014-04-01 |
| Completed | PH 2 ADI-PEG 20 Study in Non-Hodgkin's Lymphoma Subjects Who Have Failed Prior Systemic Therapy Non-Hodgkin's Lymphoma | Phase 2 | 2013-12-06 |
| Completed | Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma Cutaneous Melanoma, Uveal Melanoma, Ovarian Carcinoma or Other Advanced Solid Tumors | Phase 1 | 2012-09-01 |
| Completed | Ph 1 Study of ADI PEG 20 in Pediatric Subjects Who Are Argininosuccinate Synthetase (ASS) Deficient Argininosuccinate Synthetase Deficient | Phase 1 | 2011-12-01 |
| Completed | Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lu Solid Tumors, Prostate Cancer | Phase 1 | 2011-09-06 |
| Completed | Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior System Hepatocellular Carcinoma | Phase 3 | 2011-07-01 |